No decline in the Barrett's segment was found with PPI treatment in randomized controlled studies (1-3). In a meta-analysis in which the arms of PPI, histamine-2 receptor antagonist, and arm with no treatment were compared, while no decline in the Barrett's segment was detected in all the three arms, a significant decrease in the development of dysplasia was observed in the arm of PPI in use for more than 2-3 years (4). However, in a recently published cohort study in which 1437 patients using and not using PPI were compared, it was claimed that the long-term use of PPI could increase the risk of HGD/EAC development up to 4-5 times in BE patients (5). When we add the data of the cohort study that was recently published to the data of the meta-analysis performed by Singh et al. (4), it is seen that the positive impact of PPI therapy on the development of dysplasia in BE persists (OR: 0.46) (6). 
RECOMMENDATIONS
• Proton pump inhibitor (PPI) therapy does not decrease the length of the Barrett's segment (Level of evidence: 1b).
• There is data regarding the fact that PPI can reduce dysplasia or the development of earlystage adenocarcinoma (odds ratio (OR): 0.46).
• The treatment of PPI may be considered in patients with a diagnosis of BE and at a high risk for the development of adenocarcinoma (Prague M>3 cm, low-grade dysplasia, obesity, smoking, and advanced age), even though they are not symptomatic (Level of evidence: 2b).
